Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04250064 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma

Study acronym: LoBULarDIPG
StatusRecruiting
PhasePhase 2
Started2020-02-04
View on ClinicalTrials.gov ↗

Amendment history

2025-04-08
Study Status v5
Primary completion date2024-12→2027-12
Completion date2024-12→2029-12
2023-11-20
Study Status v4
Primary completion date2023-02→2024-12
Completion date2023-02→2024-12
2022-04-28
2 amendments v2-v3
2 re-verifications since 2021-04-12, no change to tracked fields
2020-03-20
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-02→confirmed 2020-02-04
Study sites0→1
2020-01-30
Original filing
In this study, the investigators are testing improvement in survival outcomes in DIPG patients when stratified with MR perfusion score and treated with the said protocol. Newly diagnosed DIPG patients will undergo MRI perfusion study in addition to the usual MRI at diagnosis and will be stratified into hyperperfused or hypoperfused tumours. The hyperperfused patients will receive additional low dose Bevacizumab weekly with conventional standard radiotherapy. The hypo-perfused patients will receive ultra-low-dose radiotherapy fractionation equivalent to conventional RT biological dose.
Trial Details
NCT Number NCT04250064
Lead Sponsor Tata Memorial Centre
Conditions DIPG
Enrollment 40 participants
Start Date 2020-02-04
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-11